SAB Biotherapeutics, Inc.
SABS Healthcare Biotechnology
SAB Biotherapeutics, Inc.’s revenue for fiscal 2024 (year ended December 2024) was $1.3 million, down 40.9% from fiscal 2023. In the quarter to June 2026, revenue fell 91.0%, EPS grew 74.3%, free cash flow fell 59.8% and total debt fell 5.01%, each against the same quarter a year earlier.
Follow SABS
A Balance Sheet is a financial statement that provides a snapshot of a company's assets, liabilities, and shareholders' equity at a specific point in time. It follows the formula: Assets = Liabilities + Shareholders' Equity. Key components include current and non-current assets, current and long-term liabilities, and equity. The Balance Sheet helps businesses and investors evaluate financial stability, liquidity, and capital structure. It's essential for assessing the company's ability to meet its obligations and fund future operations.
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
Cash and Short Term Investments |
+8 more quarters Free account |
110.88 | 96.59 | 107.39 | 102.63 |
Receivables |
0.56 | 0.95 | 1.56 | 1.84 | |
Total current assets |
113.28 | 101.05 | 112.78 | 107.94 | |
Property, Plant, Equpment (Net) |
13.11 | 13.31 | 13.81 | 14.23 | |
Long-Term Investments |
50.61 | 46.89 | 110.24 | 105.35 | |
Long-term assets (Other) |
3.64 | 8.81 | 8.75 | 8.80 | |
Total non-current assets |
70.17 | 71.76 | 135.69 | 130.27 | |
Total Assets |
183.45 | 172.81 | 248.47 | 238.21 | |
Accounts Payable |
2.96 | 3.15 | 3.55 | 3.86 | |
Accrued Expenses |
6.85 | 6.58 | 5.39 | 7.21 | |
Current Part of Capital Lease |
0.15 | 0.15 | 0.16 | 0.16 | |
Total current liabilities |
10.79 | 10.68 | 9.85 | 11.71 | |
Long Term Debt (Total) |
3.16 | 3.12 | 3.08 | 3.04 | |
Non-current Liabilities (Other) |
2.38 | 5.64 | 6.12 | 7.23 | |
Total non-current liabilities |
7.58 | 10.63 | 11.37 | 11.72 | |
Total liabilities |
18.37 | 21.32 | 21.22 | 23.43 | |
Additional Paid In Capital |
264.55 | 267.72 | 362.75 | 373.48 | |
Preferred Stock (Total) |
0.00 | 0.00 | 0.00 | — | |
Common Stock (Net) |
0.00 | 0.01 | 0.01 | 0.01 | |
Retained Earnings |
(94.03) | (110.89) | (129.76) | (152.25) | |
Treasury Stock |
5.52 | 5.52 | 5.52 | 5.52 | |
Common Equity (Total) |
165.07 | 151.50 | 227.25 | 214.79 | |
Shareholders Equity (Total) |
165.07 | 151.50 | 227.25 | 214.79 | |
Shareholders Equity and Liabilities (Total) |
183.45 | 172.81 | 248.47 | 238.21 | |
Shares (Common) |
47.49 | 47.61 | 75.75 | 83.49 | |
Shares (Preferred) |
0.67 | 0.67 | 0.62 | 0.55 | |
Shareholders Equity (Tangible) |
165.07 | 151.50 | 227.25 | 214.79 | |
Net Debt |
(107.72) | (93.47) | (104.31) | (99.59) | |
Total Debt |
3.16 | 3.12 | 3.08 | 3.04 |